



## DAFTAR PUSTAKA

1. Gandi M, Seprida QD, Wisesa TW, Munasir Z. Skleroderma pada Anak. 2008;9.
2. Zulian F, Tepas E. Juvenile systemic sclerosis ( scleroderma ): Assessment and approaches to treatment. 2020;
3. Torok KS. Torok KS. Pediatric scleroderma: systemic or localized forms. *Pediatric Clinics*. 2012 Apr 1;59(2):381-405. *NIH Public Access*. 2013;59:381–405.
4. Li SC. Scleroderma in Children and Adolescents: Localized Scleroderma and Systemic Sclerosis. *Pediatr Clin North Am*. 2018;65:757–81.
5. Zulian F, Tepas E. Juvenile systemic sclerosis ( scleroderma ): Classification , clinical manifestations , and diagnosis. 2020;
6. Zulian F, Tepas E. Juvenile systemic sclerosis ( scleroderma ): Assessment and approaches to treatment. 2020;
7. Rabinovich CE. Challenges in the diagnosis and treatment of juvenile systemic sclerosis. *Nat Rev Rheumatol*. 2011;7:676–80.
8. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action [Internet]. Vol. 47, *Immunopharmacology*. 2000. Available from: [www.elsevier.com/locate/immpharm](http://www.elsevier.com/locate/immpharm)
9. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - A retrospective analysis. *Rheumatology*. 2007;46:442–5.
10. Frade S, Cameron M, Espinosa-Cuervo G, Suarez-Almazor ME, Lopez-Olivo MA. Exercise and physical therapy for systemic sclerosis. Vol. 2022, *Cochrane Database of Systematic Reviews*. John Wiley and Sons Ltd; 2022.
11. Liem SIE, van Leeuwen NM, Vliet Vlieland TPM, Boerrigter GMW, van den Ende CHM, de Punder L AJ, et al. Physical Therapy in Systemic Sclerosis: The Patient Perspective. *Arthritis Care Res (Hoboken)*. 2023;75:145–51.
12. Gandi M, Seprida QD, Wisesa TW, Munasir Z. Skleroderma pada Anak. 2008;9.
13. Zulian F, Tepas E. Juvenile systemic sclerosis ( scleroderma ): Classification , clinical manifestations , and diagnosis. 2020;
14. Bairkdar M, Rossides M, Westerlind H, Hesselstrand R, Arkema E V., Holmqvist M. Incidence and prevalence of systemic sclerosis globally: A comprehensive systematic review and meta-analysis. Vol. 60, *Rheumatology (United Kingdom)*. Oxford University Press; 2021. p. 3121–33.
15. Li SC. Scleroderma in Children and Adolescents: Localized Scleroderma and Systemic Sclerosis. *Pediatr Clin North Am* [Internet]. 2018;65:757–81. Available from: <https://doi.org/10.1016/j.pcl.2018.04.002>
16. Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative. *Arthritis Rheum*. 2013;65:2737–47.
17. Editor FD, Curtis MR. Pathogenesis of systemic sclerosis ( scleroderma ). 2020;
18. Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. *Front Immunol*. 2015;6.



19. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A Randomized, Controlled Trial of Methotrexate Versus Placebo in Early Diffuse Scleroderma. Vol. 44, *ARTHRITIS & RHEUMATISM*. 2001.
20. Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Vol. 401, *The Lancet*. Elsevier B.V.; 2023. p. 304–18.
21. Chan ESL, Cronstein BN. Methotrexate how does it really work? Vol. 6, *Nature Reviews Rheumatology*. 2010. p. 175–8.
22. Bedoui Y, Guillot X, Sélambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, et al. Methotrexate an old drug with new tricks. Vol. 20, *International Journal of Molecular Sciences*. MDPI AG; 2019.
23. Kremer JM. Major adverse effects low dose MTX. *UpToDate*. 2024;
24. Andréasson K, Neringer K, Wuttge DM, Henrohn D, Marsal J, Hesselstrand R. Mycophenolate mofetil for systemic sclerosis: Drug exposure exhibits considerable inter-individual variation—a prospective, observational study. *Arthritis Res Ther*. 2020;22.
25. Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. *Rheumatology*. 2009;48:1595–9.
26. Downing HJ, Pirmohamed M, Beresford MW, Smyth RL. Paediatric use of mycophenolate mofetil. Vol. 75, *British Journal of Clinical Pharmacology*. 2013. p. 45–59.
27. Herrick AL. Controversies on the use of steroids in systemic sclerosis. Vol. 2, *Journal of Scleroderma and Related Disorders*. SAGE Publications Ltd; 2017. p. 84–91.
28. Möhlmann JE, Ezzafzafi S, Lindemans CA, Jansen MHA, Nierkens S, Huitema ADR, et al. Pharmacokinetics and Pharmacodynamics of Systemic Corticosteroids in Autoimmune and Inflammatory Diseases: A Review of Current Evidence. *Clinical Pharmacokinetics*. Adis; 2024.
29. de Pinto M, Coppi F, Spinella A, Pagnoni G, Morgante V, Macripò P, et al. The predictive role of the TAPSE/SPAP ratio for cardiovascular events and mortality in systemic sclerosis with pulmonary hypertension. *Front Cardiovasc Med*. 2024;11.
30. Stevens AM, Torok KS, Li SC, Taber SF, Lu TT, Zulian F. Immunopathogenesis of juvenile systemic sclerosis. Vol. 10, *Frontiers in Immunology*. Frontiers Media S.A.; 2019.
31. Dipasquale V, Cucinotta U, Romano C. Acute malnutrition in children: Pathophysiology, clinical effects and treatment. Vol. 12, *Nutrients*. MDPI AG; 2020. p. 1–9.
32. Bharadwaj S, Tandon P, Gohel T, Corrigan ML, Coughlin KL, Shatnawei A, et al. Gastrointestinal Manifestations, Malnutrition, and Role of Enteral and Parenteral Nutrition in Patients With Scleroderma [Internet]. 2015. Available from: [www.jcge.com](http://www.jcge.com)
33. Preis E, Franz K, Siegert E, Makowka A, March C, Riemekasten G, et al. The impact of malnutrition on quality of life in patients with systemic sclerosis. *Eur J Clin Nutr*. 2018;72:504–10.
34. Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. *Front Immunol*. 2015;6.



35. Editor FD, Curtis MR. Pathogenesis of systemic sclerosis ( scleroderma ). 2020;
36. Zanatta E, Polito P, Famoso G, Larosa M, De Zorzi E, Scarpieri E, et al. Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. Vol. 244, *Experimental Biology and Medicine*. SAGE Publications Inc.; 2019. p. 120–31.
37. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. *Ann Rheum Dis*. 2007;66:940–4.
38. Zulian F, Martini G. Systemic sclerosis in children. Vol. 2, *Future Rheumatology*. 2007. p. 51–60.
39. Ioannidis JPA, Vlachoyiannopoulos PG, Haidich AB, Medsger TA, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: An International meta-analysis of individual patient data. Vol. 118, *American Journal of Medicine*. 2005. p. 2–10.
40. Denton CP, Khanna D. Systemic sclerosis. Vol. 390, *The Lancet*. Lancet Publishing Group; 2017. p. 1685–99.
41. Connolly MK. DERMATOLOGIC THERAPY Scleroderma. *Dermatol Ther* [Internet]. 2001;14:81–94. Available from: [www.scleroderma.org](http://www.scleroderma.org)
42. Dewi S, Onkowitzaya JA, Awalia et. al. ., Diagnosis dan Pengelolaan Sklerosis Sistemik. Rekomendasi Perhimpunan Reumatologi Indonesia. 2023.
43. Moon SJ, Lee WY, Hwang JS, Hong YP, Morisky DE. Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. Vol. 12, *PLoS ONE*. Public Library of Science; 2017.
44. Keane N, Ghannam A, Fragkos KC, Rahman F. Oral, enteral and parenteral nutritional therapies in scleroderma: A systematic review. *Clin Nutr ESPEN*. 2022;51:174–84.
45. Jellinek MS, Murphy JM, Little MM, Maria E, Pagano M, Diane M, et al. Use of the Pediatric Symptom Checklist to Screen for Psychosocial Problems in Pediatric Primary Care: A National Feasibility Study. 1999.
46. HEEADSSS albin alex.
47. Marsubrin PMT. Kualitas hidup anak sindrom nefrotik menggunakan penilaian Pediatric Quality Of Life Inventorytm (PedsQLTM) = Quality of life in children with nephrotic syndrome using Pediatric Quality of Life InventoryTM (PedsQLTM).
48. Malcarne VL, Fox RS, Mills SD, Gholizadeh S. Psychosocial aspects of systemic sclerosis. Vol. 25, *Current Opinion in Rheumatology*. 2013. p. 707–13.
49. [kupdf.net\\_kepmenkes-ri-no-829-tahun-1999-persyaratan-kesehatan-perumahan](http://kupdf.net_kepmenkes-ri-no-829-tahun-1999-persyaratan-kesehatan-perumahan).